The Eli Lilly $40M investment is the key signal — it validates Absci's AI platform and pipeline, potentially opening the door for broader collaboration. Monitor for partnership announcements and ABS-201 clinical data. The at-market pricing and lock-ups limit near-term selling pressure, but the dilution is real. Watch for how the market prices the Eli Lilly endorsement against the dilution over the next few weeks.
Price Chart
Executive Summary
Absci is conducting a $100M follow-on offering of 13.5M shares at $7.41 (market price), with Eli Lilly purchasing $40M of the offering. The net proceeds of ~$93.5M will fund advancement of lead candidate ABS-201 (anti-PRLR antibody for alopecia/endometriosis) and working capital. The Eli Lilly participation is a strong strategic validation, but the ~8.7% dilution is a material offset.
Key Facts
- 13,495,277 shares offered at $7.41 per share, raising $100M gross ($93.5M net)
- Eli Lilly allocated 5,398,111 shares ($40M) of the offering at the same price
- Post-offering shares outstanding: 168,845,412 (from 155,350,135)
- Immediate dilution of $6.08 per share for new investors (offering price $7.41 vs as-adjusted book value $1.33)
- Net tangible book value increases from $131.2M ($0.84/sh) to $224.7M ($1.33/sh)
- 60-day lock-up agreements for officers and directors
- Underwriters: Jefferies, J.P. Morgan, TD Cowen, Guggenheim Securities
- Proceeds to fund ABS-201 clinical development across alopecia and endometriosis
Financial Impact
$100M gross equity raise with ~8.7% dilution; Eli Lilly's $40M strategic investment provides validation and extends cash runway through key ABS-201 milestones
Risk Factors
- ~8.7% dilution to existing shareholders
- Clinical-stage biotech with no approved products — ABS-201 still in early development
- Need for additional capital beyond this raise to fund pipeline through commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-281131 |
| Document: 0001193125-26-281131-index-headers.html | 0001193125-26-281131 |
| Document: 0001193125-26-281131-index.html | 0001193125-26-281131 |
| Document: 0001193125-26-281131.txt | 0001193125-26-281131 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | Institutional Cluster | $9.50 $9.99 | ▲ +5.16% | ▲ +5.60% | $10.31 (+8.53%) |
Jul 6, 2026 16w ago | Insider Buy | $11.33 $10.23 | ▼ −9.71% | ▼ −10.26% | $10.31 (−9.00%) |
Jun 24, 2026 17w ago | 8-K | $10.21 $11.11 | ▲ +8.81% | ▲ +7.25% | $10.31 (+0.98%) |
Jun 24, 2026 17w ago | 424B5 | $10.21 $11.11 | ▲ +8.81% | ▲ +7.25% | $10.31 (+0.98%) |
Jun 24, 2026 17w ago | Press Release | $10.08 $11.11 | ▲ +10.27% | ▲ +8.57% | $10.31 (+2.33%) |
Jun 24, 2026 17w ago | 8-K | $10.08 $11.11 | ▲ +10.27% | ▲ +8.57% | $10.31 (+2.33%) |
Jun 24, 2026 17w ago | Press Release | $10.08 $11.11 | ▲ +10.27% | ▲ +8.57% | $10.31 (+2.33%) |
Apr 23, 2026 26w ago | Press Release | $3.94 $4.98 | ▲ +26.27% | ▲ +25.36% | $10.31 (+161.68%) |
Apr 22, 2026 26w ago | DEFA14A | $3.97 $4.71 | ▲ +18.64% | ▲ +17.16% | $10.31 (+159.70%) |
Mar 24, 2026 30w ago | Press Release | $2.92 $3.15 | ▲ +7.88% | ▲ +8.12% | $10.31 (+253.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers